| Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012 |
2013 |
Critical Care Medicine (3.24) |
Dellinger, Richard Phillip |
US |
3,435 |
| The third international consensus definitions for sepsis and septic shock (sepsis-3) |
2016 |
JAMA (7.30) |
Singer, Mervyn |
UK |
2,859 |
| The pathophysiology and treatment of sepsis |
2003 |
New England Journal of Medicine (14.75) |
Hotchkiss, Richard S. |
US |
2,711 |
| Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012 |
2013 |
Intensive Care Medicine (3.99) |
Dellinger, Richard Phillip |
US |
2,409 |
| Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial |
1994 |
JAMA (7.30) |
Fisher, Charles J. |
US |
842 |
| Immunosuppression in patients who die of sepsis and multiple organ failure |
2011 |
JAMA (7.30) |
Boomer, Jonathan S. |
US |
666 |
| Novel strategies for the treatment of sepsis |
2003 |
Nature Medicine (16.81) |
Riedemann, Niels Christoph |
Germany |
635 |
| Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy |
2013 |
Nature Reviews Immunology (17.43) |
Hotchkiss, Richard S. |
US |
593 |
| A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis |
1991 |
JAMA (7.30) |
Greenman, Richard L. |
US |
583 |
| Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial |
1997 |
Critical Care Medicine (3.24) |
Opal, Steven M. |
US |
553 |
